drugset / Trial / NCT01824264
Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of the study is to evaluate the efficacy, tolerability and short-term safety of LIK066 to support dose selection for phase 3.
Timeline
- Start
- 2015-11
- Primary completion
- 2016-11
- Completion
- 2016-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sitagliptin | Small molecule | 100 mg | — |
| Subject | licogliflozin | Small molecule | 2.5 mg | — |
| Subject | licogliflozin | Small molecule | 5 mg | — |
| Subject | licogliflozin | Small molecule | 10 mg | — |
| Subject | licogliflozin | Small molecule | 25 mg | — |
| Subject | licogliflozin | Small molecule | 50 mg | — |
| Subject | licogliflozin | Small molecule | 100 mg | — |
| Subject | licogliflozin | Small molecule | 150 mg | — |